BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Israeli lawmakers pass bill reviving death penalty for terrorists - 2Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024
- 3Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- 4Well known Tea Brands for Each Tea Sweetheart
- 5Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
- Most loved Road Food: Which One Prevails upon You?
- 2024 Style: The It-Things You Want in Your Closet
- Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- Top German court to rule on claims by Wirecard shareholders
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- What an expert on the gut microbiome eats in a day
- What's your biological age? Experts explain the benefits and risks of at-home tests
- Images of Bangladeshi motorcyclists sleeping at petrol pumps are AI-generated
- Foot fossil discovery could reshape human evolutionary history
